almost
year
ago
pizzo
et
al
publish
landmark
studi
prospect
evalu
pediatr
young
adult
cancer
patient
present
fever
bacteri
fungal
organ
account
microbiolog
document
infect
febril
neutropenia
sinc
research
effort
larg
focus
strategi
reduc
prevent
morbid
mortal
relat
infect
caus
bacteri
fungal
pathogen
howev
advent
clinic
avail
array
sensit
specif
diagnost
tool
afford
clinician
research
opportun
identifi
previous
undetect
viral
pathogen
recent
literatur
link
mani
fever
neutropenia
episod
viral
pathogen
signific
morbid
mortal
attribut
virus
caus
varieti
present
either
primari
reactiv
infect
major
clinic
import
viral
pathogen
oncolog
patient
treatment
activ
infect
limit
lack
effect
antivir
therapi
host
compromis
immun
system
therefor
prevent
suppress
therapeut
measur
paramount
import
epidemiolog
relev
common
viral
pathogen
children
malign
undergo
hematopoiet
cell
transplant
hct
review
commonli
employ
prevent
suppress
measur
combat
viral
pathogen
discuss
necessari
area
futur
develop
viral
prevent
highlight
list
viral
pathogen
led
signific
infect
pediatr
patient
malign
undergo
hct
lengthi
growth
list
includ
improv
diagnost
modal
identifi
previous
exist
unrecogn
viral
pathogen
eg
human
metapneumoviru
hmpv
well
previous
identifi
virus
thought
inconsequenti
consid
import
contributor
poor
outcom
eg
human
herp
viru
epidemiolog
common
respiratori
herp
gastrointestin
virus
briefli
discuss
three
rel
larg
prospect
observ
studi
perform
comprehens
respiratori
viral
test
children
present
malign
fever
incid
identifi
respiratori
viral
pathogen
per
febril
episod
rang
variat
frequenc
identifi
pathogen
relat
variat
diagnost
test
util
specimen
type
collect
implic
test
screen
vs
symptom
guid
test
across
three
studi
commonli
identifi
viral
organ
includ
rhinoviru
respiratori
syncyti
viru
rsv
parainfluenza
influenza
adenoviru
less
frequent
hmpv
human
bocaviru
coronaviru
also
identifi
although
less
data
exist
hct
recipi
one
recent
prospect
studi
show
surveil
pcr
test
patient
receiv
allogen
hct
posit
test
primari
respiratori
pathogen
distribut
viral
isol
similar
children
malign
among
respiratori
pathogen
rsv
particular
concern
result
mortal
patient
immunocompet
patient
rsv
often
upper
respiratori
infect
howev
patient
aml
hct
recipi
rsv
progress
lower
respiratori
tract
process
set
rsv
associ
case
fatal
rate
patient
aml
case
fatal
rate
pediatr
recipi
hct
note
adenoviru
commonli
identifi
respiratori
pathogen
howev
adenoviru
also
reactiv
latent
statu
caus
signific
morbid
mortal
pediatr
hct
recipi
adenoviru
infect
rate
rang
invas
diseas
rate
rang
number
studi
suggest
rate
adenoviru
infect
pediatr
hct
recipi
higher
adult
popul
case
fatal
rate
adenoviru
infect
death
directli
attribut
adenoviru
rang
although
primari
herp
viru
infect
possibl
abil
reactiv
latenc
result
major
herp
viru
morbid
mortal
children
malign
receiv
hct
prospect
surveil
test
detect
cmv
reactiv
pediatr
allogen
hct
recipi
despit
therapi
mani
patient
cmv
reactiv
go
cmv
diseas
patient
succumb
cmv
diseas
without
acyclovir
suppress
therapi
hsv
reactiv
frequent
hsv
seroposit
adult
hct
recipi
adult
leukemia
patient
hsv
reactiv
seem
less
frequent
children
complic
episod
fever
neutropenia
prolong
mucos
similarli
herp
zoster
reactiv
common
pediatr
hct
recipi
go
dissemin
patient
acut
lymphoblast
leukemia
prospect
surveil
pediatr
allogen
hct
recipi
suggest
greater
evid
ebv
reactiv
reactiv
develop
associ
mortal
rate
greater
gain
signific
attent
concern
reactiv
viru
hct
recipi
prospect
monitor
serial
plasma
pcr
test
pediatr
allogen
hct
recipi
evid
viremia
although
extent
impact
period
clear
implic
variou
clinic
complic
neurocognit
declin
enceph
delay
engraft
secondari
graft
failur
complic
interpret
posit
pcr
test
potenti
inherit
secondari
chromosom
integr
inherit
estim
exist
world
popul
present
inherit
misinterpret
actual
reactiv
result
unnecessari
medic
intervent
tradit
test
primari
stool
viral
pathogen
limit
antigen
test
rotaviru
enter
adenoviru
serotyp
specif
incid
data
virus
children
malign
receiv
hct
avail
medic
literatur
nonetheless
impact
infect
rel
dehydr
prolong
hospit
stay
persist
symptom
need
parenter
nutrit
well
document
pcr
test
made
identif
gastrointestin
pathogen
human
calicivirus
noroviru
sapoviru
astroviru
possibl
gastrointestin
pathogen
symptom
often
pronounc
viral
shed
prolong
patient
receiv
chemotherapi
undergo
hct
infect
control
measur
serv
cornerston
infect
prevent
effort
particularli
import
regard
primari
respiratori
gastrointestin
virus
mani
pathogen
link
nosocomi
outbreak
oncolog
hct
ward
arguabl
import
infect
control
compon
maintain
healthcar
worker
hcw
complianc
hand
hygien
world
health
organ
propos
recommend
appropri
hand
hygien
techniqu
unfortun
physician
work
oncolog
pediatr
intens
care
unit
found
less
complianc
appropri
hand
hygien
practic
attempt
also
made
reduc
potenti
hcw
carri
viral
pathogen
hospit
hcw
complianc
yearli
influenza
vaccin
poor
although
heavili
debat
mandatori
influenza
vaccin
hcw
success
enact
reason
well
receiv
larg
children
hospit
also
necessari
medic
institut
maintain
polici
prevent
hcw
come
work
symptomat
communic
diseas
one
survey
hcw
report
recent
respiratori
infect
state
provid
patient
care
symptom
start
guidelin
work
restrict
set
publish
enforc
final
patient
visitor
children
adult
serv
reservoir
viral
transmiss
hospit
children
although
literatur
document
effect
screen
practic
limit
reason
employ
polici
visitor
screen
symptom
consist
infecti
process
present
restrict
visit
combin
infect
control
practic
ultim
result
reduct
nosocomi
viral
infect
therefor
collabor
infect
control
team
prove
invalu
exampl
comprehens
infect
control
initi
proven
success
reduc
nosocomi
rsv
infect
hct
unit
vaccin
effect
approach
prophylaxi
although
number
vaccin
live
viru
vaccin
thu
contraind
immunocompromis
children
still
import
encourag
famili
maintain
complianc
vaccin
recommend
close
famili
contact
practic
refer
cocoon
help
provid
protect
around
vulner
immunocompromis
patient
oral
polioviru
vaccin
longer
administ
us
live
viru
vaccin
definit
contraind
administr
household
contact
immunocompromis
patient
advisori
committe
immun
practic
offer
suggest
close
contact
patient
sever
weaken
immun
system
care
protect
environ
receiv
live
attenu
nasal
spray
influenza
vaccin
laiv
howev
suggest
support
publish
data
biolog
vaccin
actual
laiv
may
superior
trival
inactiv
vaccin
prevent
transmiss
influenza
viru
close
contact
immunocompromis
patient
laiv
recipi
local
product
mucos
iga
antibodi
neutral
wild
type
viru
portal
entri
thu
limit
potenti
shed
wild
type
viru
addit
laiv
provid
protect
circul
influenza
strain
includ
vaccin
furthermor
fear
transmiss
subsequ
infect
attenu
vaccin
viru
unfound
laiv
viru
replic
core
bodi
temperatur
given
surpris
case
document
infect
attenu
viru
close
contact
laiv
recipi
vaccin
avail
aforement
viral
pathogen
includ
influenza
varicella
rotaviru
former
routin
recommend
children
malign
undergo
hct
clearli
immun
statu
patient
time
vaccin
signific
impact
patient
respons
influenza
vaccin
seroconvers
children
receiv
chemotherapi
possibl
addit
influenza
vaccin
children
recent
complet
chemotherapi
shown
reduc
rate
respiratori
tract
infect
hospit
antibiot
despit
univers
recommend
influenza
vaccin
pediatr
oncologist
recommend
vaccin
patient
never
unsaf
administ
inactiv
influenza
vaccin
thu
administ
children
prior
start
influenza
season
even
children
previous
note
egg
allergi
influenza
vaccin
safe
perform
although
varicella
vaccin
live
attenu
vaccin
multipl
public
document
safeti
effect
vaccin
administr
children
remiss
without
suspens
mainten
chemotherapi
howev
recommend
hold
chemotherapi
around
time
vaccin
report
fatal
event
child
varicella
vaccin
rais
concern
administ
vaccin
routin
patient
hct
recipi
safe
administ
live
attenu
varicella
vaccin
variou
paramet
met
immunosuppress
agent
document
respons
inact
vaccin
demonstr
adequ
absolut
lymphocyt
count
lymphocyt
function
two
small
clinic
trial
evalu
efficaci
heat
inactiv
varicella
vaccin
three
four
dose
schedul
period
among
adult
autolog
allogen
hct
recipi
two
studi
trend
toward
reduc
herp
zoster
infect
unfortun
heat
inactiv
varicella
vaccin
current
avail
two
rotaviru
vaccin
live
oral
pentaval
vaccin
oral
live
attenu
monoval
vaccin
current
licens
unit
state
date
data
safeti
efficaci
either
vaccin
exist
children
malign
receiv
hct
therefor
neither
recommend
patient
popul
prophylaxi
primarili
limit
influenza
varicella
exposur
efficaci
influenza
chemoprophylaxi
healthi
household
contact
index
influenza
case
well
establish
random
trial
although
random
trial
specif
immunocompromis
patient
perform
cdc
recommend
support
chemoprophylaxi
close
exposur
unvaccin
patient
variou
regimen
suggest
typic
prophylaxi
begin
within
h
continu
day
choic
antivir
agent
use
guid
current
year
influenza
sensit
profil
report
cdc
influenza
vaccin
also
administ
expos
individu
recommend
varicella
prophylaxi
provid
redbook
report
committe
infecti
diseas
patient
without
histori
varicella
unknown
neg
varicella
serolog
receiv
chemotherapi
malign
recipi
hct
consid
risk
varicella
infect
true
exposur
definit
true
exposur
challeng
close
contact
someon
chicken
pox
intim
contact
someon
herp
zoster
often
consid
real
exposur
passiv
immunoprophylaxi
within
h
establish
administ
varicella
zoster
immunoglobulin
varizig
varizig
avail
routin
use
canada
unit
state
must
administ
via
investig
new
drug
protocol
fff
enterpris
http
wwwfffenterprisescomproductsvarizigaspx
varizig
avail
convent
intraven
immunoglobulin
substitut
h
time
exposur
elaps
immunoprophylaxi
less
effect
set
chemoprophylaxi
acyclovir
start
day
exposur
continu
day
administ
fisher
et
al
recent
review
avail
data
effect
approach
immunocompet
immunocompromis
children
reason
strong
data
support
effect
immunoglobulin
reduc
risk
sever
diseas
immunocompromis
children
data
effect
acyclovir
chemoprophylaxi
immunocompromis
children
limit
case
report
small
case
seri
howev
approach
effect
expos
immunocompet
children
thu
consid
reason
secondari
option
immunocompromis
host
passiv
immunoprophylaxi
rsv
immunocompromis
patient
monoclon
antibodi
palivizumab
synagi
explor
data
limit
studi
rat
immunosuppress
week
cyclophosphamid
expos
rsv
suggest
respiratori
viral
replic
reduc
palivizumab
administ
day
prior
rsv
inocul
recent
decis
tree
mathemat
model
util
estim
rate
rsv
exposur
hospit
death
pediatr
hct
recipi
conclud
monthli
palivizumab
administr
hct
recipi
would
result
decreas
mortal
although
data
compel
number
assumpt
made
execut
decis
tree
analysi
make
difficult
recommend
intervent
pediatr
patient
undergo
hct
clearli
addit
research
necessari
better
defin
benefit
palivizumab
passiv
prophylaxi
hct
recipi
data
clinic
trial
support
efficaci
prophylaxi
ganciclovir
compar
placebo
cmv
seroposit
hct
recipi
howev
neutropenia
note
risk
receiv
ganciclovir
compar
ganciclovir
therapeut
approach
differ
rate
cmv
diseas
death
addit
foscarnet
also
suggest
period
patient
due
decreas
incid
bone
marrow
suppress
clear
consensu
exist
publish
adult
recommend
support
either
prophylact
approach
hct
recipi
eg
seroposit
recipi
donor
deplet
transplant
mismatch
donor
although
cmv
diseas
report
children
receiv
chemotherapi
variou
malign
cmv
prophylaxi
patient
popul
typic
recommend
control
trial
acyclovir
prophylaxi
proven
effect
variou
adult
hct
malign
patient
popul
given
high
rate
hsv
reactiv
without
suppress
therapi
adult
guidelin
support
administr
acyclovir
prophylaxi
hsv
seroposit
allogen
hct
recipi
engraft
resolut
mucos
similar
approach
suggest
hsv
seroposit
pediatr
hct
recipi
also
deem
reason
administ
acyclovir
prophylaxi
adult
pediatr
patient
leukemia
receiv
chemotherapi
howev
monitor
treat
clinic
appar
breakthrough
hsv
infect
seem
prudent
pediatr
patient
frequenc
hsv
reactiv
like
much
less
children
patient
frequent
hsv
recurr
prolong
acyclovir
prophylaxi
discuss
famili
combin
pediatr
adult
trial
demonstr
benefit
acyclovir
prophylaxi
reduc
herp
zoster
episod
vzv
seroposit
hct
recipi
base
data
recent
publish
guidelin
support
administr
acyclovir
vzv
serolog
posit
allogen
hct
recipi
year
although
herp
zoster
infect
common
children
current
recommend
prophylaxi
patient
time
risk
quit
prolong
instead
clinic
monitor
treatment
herp
zoster
episod
suggest
acyclovir
prophylaxi
patient
two
herp
zoster
episod
consid
least
durat
chemotherapi
exposur
data
prophylact
use
antivir
direct
suppress
reactiv
adenoviru
limit
abstract
present
european
studi
group
blood
bone
marrow
transplant
suggest
ribavirin
prophylaxi
may
benefici
reduc
adenoviru
infect
mortal
pediatr
hct
recipi
versu
histor
control
data
yet
publish
current
expert
support
use
cidofovir
therapeut
approach
especi
among
hct
recipi
enter
era
advanc
commonli
avail
diagnost
modal
made
possibl
identifi
presenc
mani
viral
pathogen
technolog
help
establish
signific
impact
viral
infect
morbid
mortal
children
malign
receiv
hct
despit
knowledg
continu
pauciti
effect
intervent
avail
prevent
suppress
infect
research
effort
focu
discov
novel
therapi
effect
prevent
treat
infect
also
attract
safeti
profil
howev
even
effect
antivir
agent
vaccin
avail
often
lack
data
consensu
best
practic
recommend
therefor
time
establish
rigor
consist
guidelin
infect
control
measur
prophylact
therapi
may
effect
way
reduc
impact
viral
pathogen
guidelin
formal
propos
evalu
appropri
adjust
committe
compos
expert
repres
disciplin
oncolog
infecti
diseas
infect
control
prevent
